

[Furosemide](#)

Essential medicine status

Section:

[12. Cardiovascular medicines](#) [12.4. Medicines used in heart failure](#)

ATC codes: [C03CA01](#)

EMLc

Indication

Heart failure ICD11 code: [BD0Z](#)

INN

Furosemide

Medicine type

Chemical agent

List type

Core

Additional notes

The square box does not apply to the listing of furosemide on the EMLc

Formulations

Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule ; 10 mg per mL in 5 mL ampoule

Oral > Liquid: 20 mg per 5 mL (EMLc) ; 50 mg per 5 mL (EMLc)

Oral > Solid > tablet: 40 mg ; 20 mg

EML status history

First added in 2005 ([TRS 933](#))

Changed in 2007 ([TRS 950](#))

Changed in 2021 ([TRS 1035](#))

Changed in 2023 ([TRS 1049](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

[bumetanide](#) (ATC codes: [C03CA02](#))

[torasemide](#) (ATC codes: [C03CA04](#))

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Furosemide](#)

DrugBank

[Furosemide](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of new strength formulations of furosemide (injection 10 mg/mL in 5 mL; tablet 20 mg (EML and EMLc); oral liquid 50 mg/5 mL (EMLc). The Committee also recommended the removal of furosemide 10 mg tablets from the EMLc.